INTRODUCTION {#s1}
============

Granular cell tumors are soft tissue neoplasms believed to be of neural origin ([@WEIMCS000380C16]). Most of these tumors are benign and can be treated with surgical resection, without need for adjuvant radiation and/or chemotherapy. However, malignant granular cell tumors, comprising \<2% of all granular cell tumors, are extremely rare and aggressive. They are associated with poor prognosis, with 39% of patients succumbing to this disease within 3 yr ([@WEIMCS000380C8]). The genetic basis of malignant granular cell tumor is currently not known, and there is little knowledge with respect to its tumor biology. The current criteria for distinguishing benign, atypical, and malignant granular cell tumors are based on histological evidence. Although surgical resection can be curative for patients with localized disease, there is no effective treatment for unresectable or metastatic malignant granular cell tumors.

Recently, [@WEIMCS000380C4] reported the first documented response of a malignant granular cell tumor to pazopanib. A gene expression profiling analysis was conducted on this patient\'s tumor, and dasatinib, an inhibitor of Src family kinases, was initiated primarily because *SRC* was the most significantly overexpressed gene. After the patient failed to respond to dasatinib, pazopanib was selected because of the overexpression of *VEGFA*. Pazopanib is a potent receptor tyrosine kinase inhibitor selectively targeting EGFR types 1, 2, and 3, PDGFR α and β, C-Kit, FGFR 1 and 3, ITK, LCK, and C-FMS (encoded by *CSF1R*) ([@WEIMCS000380C21]). The patient responded to treatment with pazopanib, with an improvement in pulmonary and soft tissue metastases that was ongoing after 4 mo of therapy. Although the exact mode of action responsible for tumor response to pazopanib in this case remains unknown, this study suggests the utility of genome and expression profiling in treatment selection.

In the present study, we performed whole-genome sequencing (WGS) of a case of malignant granular cell tumor from a patient who had a metabolic response to pazopanib. This provides the first characterization of the genomic landscape of this rare disease. Our results provide insight about the genetic basis of this poorly understood and aggressive disease.

RESULTS {#s2}
=======

Clinical Presentation {#s2a}
---------------------

A 26-yr old female with no significant past medical history sought medical attention for dysphagia, multiple subcutaneous nodules, and unintentional weight loss. A laryngoscopy revealed a mass involving the posterior hypopharyngeal wall and surrounding areas. Computed tomography (CT) imaging detected a 7.2-cm heterogeneously enhancing mass centered in the posterior pharyngeal space with bilateral enlarged level II cervical lymph nodes. 18-fluorodeoxy-glucose positron emission tomography (FDG-PET) revealed FDG-avid lesions in bilateral breasts, scalp, pelvis, subcutaneous tissue of buttocks and in the left proximal humerus. Pathology review of the resection of the hypopharyngeal mass and biopsies of a subcutaneous nodule and breast lesion revealed a neoplasm that consisted of large polygonal cells with intracytoplasmic eosinophilic globules. These cells had large nuclei with mild-to-moderate atypia and occasional macronucleoli. Necrosis or spindling was not identified. The neoplastic cells were positive for S100, CD68 ([Fig. 1](#WEIMCS000380F1){ref-type="fig"}), and CD57 (not shown) immunohistochemical stains. The morphologic and immunohistochemical features were consistent with "granular cell tumor of uncertain malignant potential." However the clinical features were suggestive of a malignant phenotype with the hypopharyngeal mass presumed to be the primary site.

![Hematoxylin and eosin (H&E)-stained images of a granular cell tumor. (*A*) High magnification of pleomorphic polygonal cells with granular cytoplasm. (*B*) Granular cell neoplasm infiltrating skeletal muscle. (*C*) Positive immunohistochemical staining for S100. (*D*) Positive immunohistochemical staining for CD68.](WeiMCS000380_F1){#WEIMCS000380F1}

Treatment was initiated with gemcitabine 675 mg/m^2^ on days 1 and 8, plus docetaxel 100 mg/m^2^ on day 8 with growth factor support in a 21-d cycle. Because there was no objective response after three cycles, the patient was switched to pazopanib at 800 mg/day. Restaging FDG-PET after 3 mo of therapy showed significant interval decrease in FDG avidity of multiple lesions, including soft tissue and skeletal metastases consistent with metabolic response to therapy. FDG uptake within a large left pelvic mass resolved completely from prepazopanib maximized standard uptake value (SUV~max~) of 5.0 ([Fig. 2](#WEIMCS000380F2){ref-type="fig"}). After 6 mo on pazopanib, restaging revealed minimal increase in FDG avidity and size in some of the metastatic lesions, but with new uptake identified in the left ventricular myocardium and pericardial areas. CT angiography confirmed numerous nodules (\<1.5 cm) scattered throughout the pericardium consistent with disease progression. The patient was then changed to daily sunitinib (37.5 mg/day). Restaging after 2 mo of therapy revealed a mixed response with decreased FDG avidity within the pericardial and subcutaneous lesions, but increased uptake within the right vocal cord and in bilateral retro-orbital areas along with a new hepatic metastasis. Following two additional months on sunitinib, the patient developed further disease progression. Subsequent interventions included surgical fixation of a femoral lytic lesion, palliative resection of symptomatic pharyngeal recurrence, placement of a gastrostomy feeding tube, and radiotherapy for painful sacral and femoral bony metastases. She received fourth-line systemic treatment with doxorubicin for two cycles without response and eventually expired 28 mo from her original diagnosis of granular cell tumor.

![Representative fused FDG-PET images prior to (*A*,*B*) and 3 mo after (*C*,*D*) starting pazopanib. SUV~max~ at the left pelvic metastatic lesion was 5.0 prepazopanib (*A*) and not hypermetabolic at 3 mo (*C*). SUV~max~ in the right breast metastatic nodules was 5.8 prepazopanib (*B*) and 2.7 after treatment (*D*).](WeiMCS000380_F2){#WEIMCS000380F2}

Genomic Analyses {#s2b}
----------------

### Overall Mutation Landscape {#s2b1}

The current granular cell tumor sample demonstrated a low mutation burden ([Fig. 3](#WEIMCS000380F3){ref-type="fig"}). Using a previous definition ([@WEIMCS000380C26]), the current WGS analysis identified 17 tier-1 mutations in gene coding regions, splice sites or noncoding RNA; 81 tier-2 mutations in regulatory or evolutionarily conserved regions of the genome; and 541 tier-3 mutations in other nonrepetitive regions of the genome. All 17 tier-1 mutations were confirmed by Sanger sequencing. The background mutation rate (BMR) was estimated to be 0.18 mutations per million covered base pairs (Mbp), which is low compared with most other common adult cancers ([@WEIMCS000380C14]). The mutation signature was dominated by C\>T transitions, mostly when adjacent to a 5′ G ([Fig. 4](#WEIMCS000380F4){ref-type="fig"}). No small insertion/deletions (indels) were detected in gene coding regions in this tumor. In addition to point mutations, we identified and validated 12 structural variations (SVs), and 22 copy-number variations (CNVs).

![Circos plot ([@WEIMCS000380C15]) depicting genetic alterations identified by WGS analyses in granular cell tumor. From outer to inner components: amino-acid-changing point mutations in genes (red, truncating mutations including nonsense and splice-site single-nucleotide variants (SNVs); orange, alternating mutations including missense SNVs; gray, nonamino-acid-changing mutations, including silent or noncoding SNVs), chromosomes, variant allele frequency (VAF) bars for the corresponding point mutation (range = \[0:1\], the color of the VAF bar indicates coverage: light gray = 0--9×; gray = 10--29×; black = ≥30×), copy-number variations (red, gain; blue, loss), loss of heterozygosity, structural variations (red, insertion; blue, deletion; purple, intrachromosomal translocation; green, interchromosomal translocation).](WeiMCS000380_F3){#WEIMCS000380F3}

![The mutational signature of the granular cell tumor. Each single-nucleotide substitution is categorized into the 96 distinct trinucleotide mutation types, depending on the substitution class (C\>A, C\>G, C\>T, T\>A, T\>C, or T\>G) and the neighboring bases (A, C, G, or T) immediately 3′ and 5′ to the mutated base. The number of mutations in each category is divided by the abundance of its trinucleotide in the reference genome to give a fractional count. The fractional count is then normalized and displayed as the percent attribution to a specific mutation type in the plot.](WeiMCS000380_F4){#WEIMCS000380F4}

### Genes Affected by Point Mutations {#s2b2}

The 17 validated tier-1 mutations in genes included six missense single-nucleotide variants (SNVs), three nonsense SNVs, and eight other SNVs not predicted to cause amino acid changes ([Fig. 3](#WEIMCS000380F3){ref-type="fig"}). For the nine amino-acid-changing SNVs, their variant allele frequencies (VAFs) ranged from 14% to 60% ([Table 1](#WEIMCS000380TB1){ref-type="table"}). No mutations were found in Cancer Gene Census genes ([@WEIMCS000380C10]). However, one nonsense SNV was identified in *BRD7* ([Fig. 5](#WEIMCS000380F5){ref-type="fig"}), a newly recognized tumor suppressor candidate that is required for TP53 function ([@WEIMCS000380C6]). Additionally, one missense SNV was found in a neurotrophic factor receptor *GFRA2*, which, upon binding of neurturin, activates RET tyrosine kinase ([@WEIMCS000380C1]).

![The *BRD7* nonsense mutation identified by WGS. (*A*) The protein domain view of BRD7 with the R613\* nonsense mutation. (*B*) Sanger sequencing chromatograms confirming the somatic status of the mutation. The mutant peak is off-center and only slightly above baseline, presumably because of the allelic burden of this variant being barely above 20%. We repeated the experiment twice and the pattern was consistent in both runs.](WeiMCS000380_F5){#WEIMCS000380F5}

###### 

Point mutations predicted to introduce amino acid changes

  GeneName    Chr     GRCh37 position   Ref\>Alt   GenBank accession    Predicted effect  Class      WGS reads (mut/total)   VAF in tumor %   
  ----------- ------- ----------------- ---------- ------------------- ------------------ ---------- ----------------------- ---------------- ----
  *ATP6AP1*   chrX    153664066         C\>A       NM_001183                 Y414\*       Nonsense   18/30                   0/16             60
  *GFRA2*     chr8    21608169          G\>A       NM_001495                 S242F        Missense   18/49                   0/27             37
  *TXNDC16*   chr14   52937263          A\>C       NM_020784                 L483\*       Nonsense   12/40                   0/44             30
  *BRD7*      chr16   50353864          G\>A       NM_001173984              R613\*       Nonsense   7/34                    0/27             21
  *MAP3K9*    chr14   71199588          G\>A       NM_033141                 T847M        Missense   8/26                    0/18             31
  *PPFIBP2*   chr11   7670871           C\>T       NM_003621                 R703W        Missense   11/35                   0/29             31
  *UBE2H*     chr7    129497389         C\>T       NM_003344                  C87Y        Missense   12/47                   0/47             26
  *MXRA5*     chrX    3240233           G\>A       NM_015419                 R1165W       Missense   6/32                    0/22             19
  *ITGA1*     chr5    52225500          G\>A       NM_181501                 E914K        Missense   9/65                    0/33             14

WGS, whole-genome sequencing; VAF, variant allele frequency.

### Somatic Structural Variations {#s2b3}

We identified 12 somatic SVs, including six deletions (DELs), four intrachromosomal translocations (ITXs), one insertion (INS), and one interchromosomal translocation (CTX) ([Table 2](#WEIMCS000380TB2){ref-type="table"}). The majority of the intrachromosomal rearrangements occurred within Chromosome 12 (two DELs, two ITXs, one INS) and Chromosome 21 (two ITXs, two DELs). Additionally, Chromosomes 2 and 9 were found to each harbor one DEL. The only CTX occurred between Chromosomes 5 and 21. The complex rearrangements on Chromosome 21 contained five SVs, where several breakpoints were located within the same region ([Fig. 6](#WEIMCS000380F6){ref-type="fig"}). All identified somatic SVs were experimentally validated by polymerase chain reaction and Sanger sequencing.

###### 

Structural variations identified by whole-genome sequencing

  ChrA   GRCh37 PosA   Orient A   Num Reads A   ChrB   GRCh37 PosB   Orient B   Num Reads B   Type   Gene^a^
  ------ ------------- ---------- ------------- ------ ------------- ---------- ------------- ------ -----------------
  12     512012        \+         2             12     28683009      \+         3             DEL    *CCDC77_CCDC91*
  12     31929644      −          1             12     31221648      \+         2             ITX    *DDX11-AS1*
  12     31835817      \+         3             12     30028522      −          0             ITX    *AMN1*
  21     15950538      \+         4             21     48047093      \+         2             DEL    *SAMSN1*
  21     36981223      \+         4             21     48033053      \+         2             DEL    
  21     48048095      −          6             21     36989776      \+         3             ITX    
  21     37092441      \+         1             5      2243357       \+         6             CTX    
  9      92290776      \+         3             9      92290847      \+         0             DEL    
  12     120004464     \+         3             12     120025731     \+         0             DEL    
  12     32142064      \+         4             12     31797004      \+         2             INS    *KIAA1551*
  21     20846107      \+         16            21     48047298      −          0             ITX    
  2      133400741     \+         2             2      133400857     \+         6             DEL    

DEL, deletion; INS, insertion; ITX, intrachromosomal translocation; CTX, interchromosomal translocation.

^a^Includes genes overlapping with the breakpoints according to Ref-seq.

![Complex rearrangement of Chromosome 21. A total of five structural variations were identified on Chromosome 21. The lines connecting different genomic locations, as well as their orientations, were identified by the CREST program. All structural variations were experimentally validated. The sizes of segments and their distances are not in proportion to the actual genomic distance.](WeiMCS000380_F6){#WEIMCS000380F6}

None of the identified SVs were predicted to cause an overexpressed gene fusion. One DEL on Chromosome 12 joined two genes---*CCDC77* and *CCDC99*---but was not in the same reading frame. Predicted truncating SVs were identified in four genes: *DDX11*-*AS1*, *AMN1*, *SAMSN1*, and *KIAA1551*.

### Somatic Copy-Number Variations and Loss of Heterozygosity {#s2b4}

Analyzing WGS data identified 22 regions with CNVs. Several whole-chromosome gains were detected for Chromosomes 5, 8, 17, 19, 20, and X. The gain of Chromosomes 8 was composed of several segments with different copy-number amplitudes. Chromosome 21 contained several gains as well as losses coupled with loss of heterozygosity, which was consistent with the identified SVs. Chromosome 12 had a one-copy loss of the p-arm with loss of heterozygosity (LOH). Copy-neutral LOH was observed across the entire Chromosome 18. Focal CNVs was one mechanism of introducing tumorigenic alterations ([@WEIMCS000380C24]). We identified four focal CNV segments containing \<10 genes ([Table 3](#WEIMCS000380TB3){ref-type="table"}). However, none of the contained genes have been implicated in cancer.

###### 

Copy-number variations identified by whole-genome sequencing

  Chr   Start      End         num.mark^a^   seg.mean^a^   Focal CNV^b^ genes                  Overexpressed in [@WEIMCS000380C4]
  ----- ---------- ----------- ------------- ------------- ----------------------------------- ------------------------------------
  2     89830501   89880100    469           1.362                                             
  5     11701      180785400   1,646,623     0.416                                             
  8     33501      43820800    400,545       0.377                                             *GNRH1*
  8     46847001   47000100    1141          0.374                                             
  8     47064701   47086300    216           0.425                                             
  8     47175401   47237700    598           0.308                                             
  8     47255701   47284200    268           0.395                                             
  8     47359501   146303800   934,229       0.413                                             *LYN*
  10    18841301   18862700    200           0.521         *NSUN6*                             
  12    60701      28683000    265,733       --0.201                                           
  12    30028501   31221500    11,065        --0.252       *IPO8, CAPRIN2, TSPAN11*            
  12    31798301   32143600    3,267         0.393         *C12orf72, AMN1, H3F3C, C12orf35*   
  17    1          81195100    704,846       0.273                                             *BRCA1, SSTR2, TOP2A*
  19    89201      59118800    510,602       0.346                                             
  20    60001      62965000    566,176       0.339                                             *OGFR, SRC*
  21    15810801   20846100    47,794        0.461                                             
  21    27262601   36981200    92,904        0.401                                             
  21    36981201   36989800    86            --0.212                                           
  21    36989801   37092400    1014          0.36                                              
  21    37092401   48033100    104,439       --0.203                                           
  21    48033101   48119800    647           0.332         *PRMT2*                             
  X     2699501    154930300   1,313,803     0.401                                             *POLA1*

num.mark, number of fixed-size windows (100 bp) in the segment; seg.mean, the estimated GC-corrected signal difference between tumor and normal. Definitions according to CONSERTING ([@WEIMCS000380C3]).

^a^"Focal CNV" defined as copy-number variations containing less than 10 genes.

In the previous gene expression study of one malignant granular cell tumor, [@WEIMCS000380C4] identified 16 overexpressed genes. In the current WGS data, eight of these 16 genes were located in CNV regions including *SRC*, *TOP2A*, *GNRH1*, *BRCA1*, *OGFR*, *POLA1*, *SSTR2*, and *LYN*. All of the involved CNVs were gains ([Table 3](#WEIMCS000380TB3){ref-type="table"}).

DISCUSSION {#s3}
==========

Malignant granular cell tumor, often associated with unresectable disease or metastatic presentation, is exceedingly rare with no effective treatment available. In addition, there is a paucity of knowledge of the genomic profile of this neoplasm. A recent study by [@WEIMCS000380C4] reported the first documented response of a malignant granular cell tumor to a systemic agent, pazopanib. We report the first whole-genome sequencing of a malignant granular cell tumor in a patient who had a striking metabolic response to pazopanib.

We found a loss-of-function mutation in *BRD7* (bromodomain-containing 7), a subunit of PBAF-specific *SWI/SNF* chromatin remodeling complexes. As a recently recognized tumor-suppressor candidate, BRD7 is required for TP53 function by affecting histone acetylation during p53 activation, and is also a regulator of BRCA1 ([@WEIMCS000380C12]). In breast cancers, it has been reported that BRD7 expression is lost in as many as 20% of the cases that contained wild-type TP53 ([@WEIMCS000380C6]; [@WEIMCS000380C12]). The locus 16q12 containing the *BRD7* gene is a known target in cancer, which has shown to be affected by focal deletions in 2.68% of all cancers ([@WEIMCS000380C2]). In addition to deletions, there have been efforts to locate *BRD7* point mutations in cancer. One such study failed to identify any truncating mutation of *BRD7* in triple negative breast cancers ([@WEIMCS000380C19]). The same *BRD7* mutation as the current one (R613\*) has been found in four previously published cancer samples according to COSMIC (annotated as R612\* using a different isoform) ([@WEIMCS000380C9]). Notably, the *BRD7* nonsense mutation reported here was predicted to remove the last 40 amino acids near the carboxy terminus ([Fig. 5](#WEIMCS000380F5){ref-type="fig"}). Further experiments are warranted to investigate the functional role of BRD7 in malignant granular cell tumors.

Pazopanib is a potent tyrosine kinase inhibitor. The known targets of pazopanib include VEGFR types 1, 2, and 3, PDGFR α and β, C-Kit, FGFR 1 and 3, ITK, LCK, and C-FMS (encoded by *CSF1R*) ([@WEIMCS000380C4]). However, in our case study, no somatic mutations were identified in any of these genes. The only identified mutation in receptor tyrosine kinase pathways was *GFRA2* (GDNF family receptor alpha 2), encoding for the primary receptor for neurturin. Neurturin is a neurotrophic factor, which is responsible for the growth, survival, and maintenance of neurons ([@WEIMCS000380C5]). Neurturin belongs to the glial cell line--derived neurotrophic factor family of ligands and has been considered a candidate for treating Parkinson disease ([@WEIMCS000380C13]). Upon activation by neurturin, GFRA2 mediates tyrosine autophosphorylation and activates the RET tyrosine kinase receptor ([@WEIMCS000380C1]). If GFRA2 is altered by a gain-of-function mutation, GFRA2 and the RET signaling pathway could potentially be activated. The *GFRA2* mutation in the current case is predicted to have changed amino acid 242, a conservative residue across many species (data not shown), from serine to phenylalanine. Further functional studies using in vivo or in vitro systems to determine whether increased phosphorylation of the RET or other receptor tyrosine kinase targets of pazopanib is observed with the *GFRA2* mutant gene will be essential to fully characterize the identified *GFRA2* mutation.

The current whole-genome sequencing only generated a limited 38.6× average coverage in tumor. Given the fact that in the current case tumor cellularity was high (estimated at 90%), which was also supported by the VAFs of observed coding mutations, the current analysis should be sensitive in capturing major clone mutations. In the future, targeted deep sequencing on a larger set of variants may provide higher sensitivity in finding subclonal mutations. Moreover, additional RNA-seq analyses may provide important insight into the gene expression profile, potential fusion transcripts, and splicing variants.

In summary, we present the first, to our knowledge, whole-genome characterization of a malignant granular cell tumor. The tumor exhibited low mutation burden and an overall stable genome with local complex rearrangements. A loss-of-function mutation was detected in a newly identified tumor suppressor candidate, *BRD7*. None of the known targets of pazopanib were mutated in this patient who demonstrated metabolic response to pazopanib, but our mutation list contains a receptor tyrosine kinase pathway mutation in *GFRA2*, which may help to elucidate the mechanism of pazopanib response. While this current study includes only one malignant granular cell tumor, it provides the first reference for future research and clinical efforts aiming to advance our understanding of this rare cancer type, which could ultimately lead to the development of focused genetic testing and personalized treatment.

METHODS {#s4}
=======

Whole-Genome Sequencing (WGS) {#s4a}
-----------------------------

The current tumor was estimated to have 90% cellularity. DNA libraries for the tumor and matching germline blood DNA were prepared using the TruSeq DNA Sample v2 preparation kit (Illumina) according to the manufacturer\'s instructions. Briefly, 1 µg of each DNA sample was fragmented using Covaris shearing to a size range of 300--400 bp (Covaris). Following end repair and 3′ adenylation, indexing adapters were ligated to the fragment ends. Following purification, the fragmented DNA was PCR amplified for five cycles, purified, and validated for appropriate size on a 2100 Bioanalyzer High Sensitivity DNA chip (Agilent Technologies). Each DNA library was quantitated using quantitative PCR (KAPA Biosystems) prior to normalization. Libraries were loaded and clustered to individual lanes of a HiSeq Flow Cell using an Illumina cBot (TruSeq PE Cluster Kit v3), followed by 2 × 100 cycle paired-end WGS on a HiSeq2000 sequencer according to the manufacturer\'s recommended protocol (Illumina). Image analysis and base calling were carried out by Illumina Software CASAVA v 1.8.2 with default parameters.

WGS Data Analyses {#s4b}
-----------------

Using a high-throughput paired-end sequencing approach, 2.6 billion 100-bp reads were generated from the tumor sample; 87% of the reads were successfully mapped to the human reference genome. Sequencing the normal sample yielded 1.3 billion reads with a 91% mapping rate. The average genome coverage was 38.6× and 30.5× in the tumor and normal samples, respectively, where 89.9% and 86.4% of the genome was covered with at least 20× coverage (Supplemental Table S1).

The bioinformatics analysis began by utilizing high quality paired-end reads passing Illumina RTA filter aligned to the NCBI human reference genome (hg19) using BWA ([@WEIMCS000380C17]). PCR duplicated reads were marked using Picard (<http://picard.sourceforge.net/>). Putative SNVs and indels were identified by running variation detection module of Bambino ([@WEIMCS000380C7]). After initial variant calling, the predicted mutations were further filtered to remove potential false calls: (1) the alternative alleles were present in both tumor and the matched normal samples and the Fisher\'s exact test *P* value equal to or larger than 0.05; (2) the mutant alleles were only present in one of the two stands and the Fisher\'s exact test *P* \< 0.05; (3) the putative mutation occurred at a site with systematically dropped base quality scores, defined by \>70% of the mutant reads with Phred quality score reduced by at least 10 at the mutant site compared with the 5′ or 3′ side neighboring bases. Putative indels were evaluated by a realignment process to filter out false calls introduced by germline events, mapping artifacts, and homopolymer. Prior to validation, the predicted mutations were manually inspected using Bambino viewer ([@WEIMCS000380C7]) to remove false calls introduced by mapping or alignment artifacts. The putative mutations passing manual review were segregated into high and low confidence groups according to their supporting information, such as the number of supporting reads, the variant allele fraction, and the coverage in the matched normal sample. The identified somatic mutations were compared with the public human germline databases, including dbSNP ([@WEIMCS000380C20]), 1000 Genomes Project (The 1000 [@WEIMCS000380C11]), National Heart, Lung, and Blood Institute\'s Exome Sequencing Project ([@WEIMCS000380C18]). The mutations were annotated by ANNOVAR ([@WEIMCS000380C22]) using RefSeq sequence database downloaded from NCBI on 22 March 2015. Mutations were classified into four tiers following previously described definitions ([@WEIMCS000380C25],[@WEIMCS000380C26], [@WEIMCS000380C27]), including tier-1 mutations occurring in gene coding regions, splice sites, or noncoding RNA according to RefSeq; tier-2 mutations in regulatory regions annotated by UCSC annotation (regulatory annotations included are targetScanS, ORegAnno, tfbsConsSites, vistaEnhancers, eponine, firstEF, L1 TAF1 Valid, Poly(A), switchDbTss, encodeUViennaRnaz, laminB1, cpgIslandExt) or evolutionarily conserved genomic regions defined by a conservation score equal to or \>500 based on either the phastConsElements28way table or the phastConsElements17way table from the UCSC Genome Browser (<http://genome.ucsc.edu/>); tier-3 mutations in any other nonrepetitive regions; and tier-4 all other mutations. Structural variations were initially detected by using CREST ([@WEIMCS000380C23]) and then manually reviewed using Bambino viewer ([@WEIMCS000380C7]). Potential fusion products between genetic regions were also predicted by considering the orientation and break points of the SVs. CNVs were detected using CONSERTING, a copy-number analysis method for WGS data ([@WEIMCS000380C3]). Only CNVs with "seg.mean" and "log.ratio" absolute value no less than 0.2 were considered for downstream analyses.

Sanger Sequencing---Variant Confirmation {#s4c}
----------------------------------------

PCR primers (IDT) were designed to flank the variant positions using Primer3 ([@WEIMCS000380C28]; [@WEIMCS000380C29]). All primers are included in Supplemental Table S2. Amplification products for each sample were generated by 35 cycles of PCR using 20-ng template DNA. The products were purified and thermal cycled for 35 cycles of 96°C (20 sec), 50°C (5 sec), and 60°C (3 min) with an appropriately diluted BigDye Terminator v.3.1 Cycle Sequencing Kit (Life Technologies). Following incubation at 12°C, the products were purified over hydrated Sephadex G-50 (Sigma-Aldrich) in 45 micron Multiscreen HV filter plates (Merck Millipore). The eluted fluorescently tagged products were then detected on an ABI Prism 3130xl Genetic Analyzer (Life Technologies) using POP-7 Polymer on a 50-cm Array according to manufacturer\'s specifications. The data were then analyzed for variants using Mutation Surveyor DNA Variant Analysis Software (Softgenetics). In the current study, 9 out of 11 high confidence SNVs and 8 out of 19 low confidence SNVs were validated as somatic mutations. For validation of SVs, two sets of primers were designed spanning junction. Amplification of the novel amplicon with these primers sets was visualized on an ethidium bromide agarose gel and then sequenced to confirm breakpoints. We validated 12 out of the 13 putative SVs.
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